Difference between revisions of "Example orders for Irinotecan (Camptosar) in colon cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.''' {{TOC...")
 
m (categories)
Line 28: Line 28:
 
'''Comments:'''
 
'''Comments:'''
 
*In contrast to the original regimen, my institution does not specifically mandate that patients with ECOG performance status 2 or higher should have a dose reduction of irinotecan.
 
*In contrast to the original regimen, my institution does not specifically mandate that patients with ECOG performance status 2 or higher should have a dose reduction of irinotecan.
 +
 +
[[Category:Example chemotherapy order sets]]

Revision as of 00:48, 20 September 2012

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.


Irinotecan (Camptosar)

Original references may be found at Irinotecan (Camptosar)

Example regimen #1

21-day cycles

Supportive medications:

  • Ondansetron (Zofran) 8 mg IV 30 minutes prior to chemotherapy
  • Dexamethasone (Decadron) 10 mg IV 30 minutes prior to chemotherapy
  • Atropine 0.4 mg IV prn diaphoresis, visual changes, abdominal cramping, or diarrhea during or after irinotecan

Hydration:

  • 500 ml NS at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS.

Monitoring:

  • Dose reduction of Irinotecan (Camptosar) to 300 mg/m2 IV over 90 minutes on day 1 is recommended for patients over 70 years old or with prior pelvic radiation.
  • Hold for significant diarrhea, ANC <1000, or platelets <100, and notify physician.

Outpatient medications:

  • Loperamide (Imodium) 4 mg PO x1 for each day's first episode of diarrhea; 2 mg PO prn each loose stool thereafter, up to a maximum of 16 mg per day

Comments:

  • In contrast to the original regimen, my institution does not specifically mandate that patients with ECOG performance status 2 or higher should have a dose reduction of irinotecan.